JP2013525469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013525469A5 JP2013525469A5 JP2013508506A JP2013508506A JP2013525469A5 JP 2013525469 A5 JP2013525469 A5 JP 2013525469A5 JP 2013508506 A JP2013508506 A JP 2013508506A JP 2013508506 A JP2013508506 A JP 2013508506A JP 2013525469 A5 JP2013525469 A5 JP 2013525469A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- formula
- halogen
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 18
- 229910052736 halogen Inorganic materials 0.000 claims 18
- 150000002367 halogens Chemical class 0.000 claims 18
- 239000012453 solvate Substances 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 8
- -1 trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl Chemical group 0.000 claims 8
- 125000004953 trihalomethyl group Chemical group 0.000 claims 8
- 125000004414 alkyl thio group Chemical group 0.000 claims 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000004768 (C1-C4) alkylsulfinyl group Chemical group 0.000 claims 4
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 4
- XXHKHLYABSAFDW-UHFFFAOYSA-N 5-amino-5-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]pentane-1,3-diol Chemical compound C1=C(Cl)C(C(CC(O)CCO)N)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 XXHKHLYABSAFDW-UHFFFAOYSA-N 0.000 claims 4
- 125000004849 alkoxymethyl group Chemical group 0.000 claims 4
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 4
- 150000004677 hydrates Chemical class 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 2
- JZHXIFZZZFFZBQ-XMMPIXPASA-N [(2r)-2-amino-4-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]-2-(hydroxymethyl)butyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@](CO)(N)COP(O)(O)=O)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 JZHXIFZZZFFZBQ-XMMPIXPASA-N 0.000 claims 2
- JZHXIFZZZFFZBQ-DEOSSOPVSA-N [(2s)-2-amino-4-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]-2-(hydroxymethyl)butyl] dihydrogen phosphate Chemical compound C1=C(Cl)C(CC[C@@](CO)(N)COP(O)(O)=O)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 JZHXIFZZZFFZBQ-DEOSSOPVSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000006372 monohalo methyl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 206010003671 Atrioventricular Block Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000003288 anthiarrhythmic effect Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 230000002763 arrhythmic effect Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000011221 initial treatment Methods 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 206010042772 syncope Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 0 **C(*)C(*)(*)N Chemical compound **C(*)C(*)(*)N 0.000 description 1
- JLFCVPLJWDRWDT-VWLOTQADSA-N C=P(O)(O)OC[C@](CCc(c(Cl)c1)ccc1Sc1cc(OCc2ccccc2)ccc1)(CO)N Chemical compound C=P(O)(O)OC[C@](CCc(c(Cl)c1)ccc1Sc1cc(OCc2ccccc2)ccc1)(CO)N JLFCVPLJWDRWDT-VWLOTQADSA-N 0.000 description 1
- NYPIIMZBDFKVOJ-RUZDIDTESA-N CP(O)(OC[C@@](CCc(c(Cl)c1)ccc1Sc1cc(OCc2ccccc2)ccc1)(CO)N)=O Chemical compound CP(O)(OC[C@@](CCc(c(Cl)c1)ccc1Sc1cc(OCc2ccccc2)ccc1)(CO)N)=O NYPIIMZBDFKVOJ-RUZDIDTESA-N 0.000 description 1
- IINUNQPYJGJCJI-UHFFFAOYSA-N NC(CCc(c(Cl)c1)ccc1Sc1cc(OCc2ccccc2)ccc1)(CO)CO Chemical compound NC(CCc(c(Cl)c1)ccc1Sc1cc(OCc2ccccc2)ccc1)(CO)CO IINUNQPYJGJCJI-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10162082.1 | 2010-05-06 | ||
| EP10162082 | 2010-05-06 | ||
| PCT/EP2011/057210 WO2011138398A1 (en) | 2010-05-06 | 2011-05-05 | Dosage regimen of diaryl sulfide derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016081108A Division JP6290963B2 (ja) | 2010-05-06 | 2016-04-14 | ジアリールスルフィド誘導体の投与レジメン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013525469A JP2013525469A (ja) | 2013-06-20 |
| JP2013525469A5 true JP2013525469A5 (enExample) | 2014-05-29 |
Family
ID=42236590
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013508506A Withdrawn JP2013525469A (ja) | 2010-05-06 | 2011-05-05 | ジアリールスルフィド誘導体の投与レジメン |
| JP2016081108A Expired - Fee Related JP6290963B2 (ja) | 2010-05-06 | 2016-04-14 | ジアリールスルフィド誘導体の投与レジメン |
| JP2018020950A Active JP6615247B2 (ja) | 2010-05-06 | 2018-02-08 | ジアリールスルフィド誘導体の投与レジメン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016081108A Expired - Fee Related JP6290963B2 (ja) | 2010-05-06 | 2016-04-14 | ジアリールスルフィド誘導体の投与レジメン |
| JP2018020950A Active JP6615247B2 (ja) | 2010-05-06 | 2018-02-08 | ジアリールスルフィド誘導体の投与レジメン |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20130210924A1 (enExample) |
| EP (1) | EP2566473B1 (enExample) |
| JP (3) | JP2013525469A (enExample) |
| KR (1) | KR20130098885A (enExample) |
| CN (2) | CN102917698A (enExample) |
| AU (1) | AU2011249789B2 (enExample) |
| BR (1) | BR112012028248A2 (enExample) |
| CA (1) | CA2794607A1 (enExample) |
| EA (1) | EA201201515A1 (enExample) |
| ES (1) | ES2562416T3 (enExample) |
| MX (1) | MX2012012925A (enExample) |
| WO (1) | WO2011138398A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI519539B (zh) | 2010-12-21 | 2016-02-01 | Kyorin Seiyaku Kk | Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof |
| LT2958624T (lt) * | 2013-02-20 | 2021-08-10 | Priothera Limited | Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas |
| EP4438037A1 (en) * | 2021-01-28 | 2024-10-02 | Priothera SAS | Methods of treatment with s1p receptor modulators |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003029184A1 (en) | 2001-09-27 | 2003-04-10 | Kyorin Pharmaceutical Co., Ltd. | Diaryl ether derivative, addition salt thereof, and immunosuppressant |
| AU2002332289B2 (en) * | 2001-09-27 | 2007-05-10 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivative, addition salt thereof, and immunosuppressant |
| US7482491B2 (en) | 2002-09-19 | 2009-01-27 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivative, addition salt thereof, and immunosuppressant |
| WO2004074297A1 (ja) | 2003-02-18 | 2004-09-02 | Kyorin Pharmaceutical Co., Ltd. | アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤 |
| MXPA06002349A (es) | 2003-08-28 | 2006-05-22 | Novartis Ag | Derivados de aminopropanol. |
| AU2005264431B2 (en) * | 2004-07-16 | 2010-08-19 | Kyorin Pharmaceutical Co., Ltd. | Method of effectively using medicine and method concerning prevention of side effect |
| JPWO2006041015A1 (ja) * | 2004-10-12 | 2008-05-15 | 杏林製薬株式会社 | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
| US20090275553A1 (en) * | 2004-11-29 | 2009-11-05 | Kovarik John M | Dosage regimen of an s1p receptor agonist |
| CA2820510A1 (en) * | 2005-09-09 | 2007-03-15 | Novartis Ag | Treatment of autoimmune diseases |
| BRPI0909625B1 (pt) * | 2008-03-17 | 2021-09-08 | Actelion Pharmaceuticals Ltd | Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1 |
| EP2328571B1 (en) * | 2008-08-18 | 2014-06-18 | Novartis AG | Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies |
| SI3409274T1 (sl) * | 2008-12-22 | 2020-03-31 | Novartis Ag | Režim odmerjanja za S1P receptor agonist |
| BRPI0923213A2 (pt) * | 2008-12-22 | 2016-01-26 | Novaris Ag | regime de dosagem de um agonista do receptor para s1p. |
-
2011
- 2011-05-05 AU AU2011249789A patent/AU2011249789B2/en not_active Expired - Fee Related
- 2011-05-05 MX MX2012012925A patent/MX2012012925A/es not_active Application Discontinuation
- 2011-05-05 ES ES11720419.8T patent/ES2562416T3/es active Active
- 2011-05-05 US US13/643,324 patent/US20130210924A1/en not_active Abandoned
- 2011-05-05 JP JP2013508506A patent/JP2013525469A/ja not_active Withdrawn
- 2011-05-05 EP EP11720419.8A patent/EP2566473B1/en active Active
- 2011-05-05 EA EA201201515A patent/EA201201515A1/ru unknown
- 2011-05-05 KR KR1020127031867A patent/KR20130098885A/ko not_active Withdrawn
- 2011-05-05 BR BR112012028248A patent/BR112012028248A2/pt not_active IP Right Cessation
- 2011-05-05 CN CN2011800227113A patent/CN102917698A/zh active Pending
- 2011-05-05 WO PCT/EP2011/057210 patent/WO2011138398A1/en not_active Ceased
- 2011-05-05 CA CA2794607A patent/CA2794607A1/en not_active Abandoned
- 2011-05-05 CN CN201610590854.9A patent/CN106309416A/zh active Pending
-
2014
- 2014-07-28 US US14/341,891 patent/US20140336265A1/en not_active Abandoned
-
2016
- 2016-04-14 JP JP2016081108A patent/JP6290963B2/ja not_active Expired - Fee Related
- 2016-10-19 US US15/297,683 patent/US20170119702A1/en not_active Abandoned
-
2017
- 2017-12-07 US US15/834,482 patent/US20180161290A1/en not_active Abandoned
-
2018
- 2018-02-08 JP JP2018020950A patent/JP6615247B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6931019B2 (ja) | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター | |
| JP2024129030A (ja) | Ｓ１ｐ受容体アゴニストの投与レジメン | |
| JP4846063B2 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| US10813890B2 (en) | Pharmaceutical combination | |
| JP2014502641A5 (enExample) | ||
| JP5496653B2 (ja) | ３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）−フェノール、およびパラセタモールを含む医薬の組合せ | |
| JP2017071636A (ja) | 医薬配合剤 | |
| RU2009144846A (ru) | Использование модулятора рецептора s1p | |
| RU2007124327A (ru) | Курс лечения с использованием агониста рецептора s1p | |
| JP2016509050A5 (enExample) | ||
| JP2013525469A5 (enExample) | ||
| US20040235922A1 (en) | Compositions and methods for inducing adipose tissue cell death | |
| JP2012501987A (ja) | ６−ジメチルアミノメチル−１−（３−メトキシフェニル）−シクロヘキサン−１，３−ジオールとｎｓａｉｄを含む医薬の組み合わせ | |
| JP6615247B2 (ja) | ジアリールスルフィド誘導体の投与レジメン | |
| JP7208139B2 (ja) | 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 | |
| JP2013530937A5 (enExample) | ||
| AR088453A1 (es) | Regimen de dosificacion del agonista o modulador del receptor de s1p | |
| JP2012501985A (ja) | ６−ジメチルアミノメチル−１−（３−メトキシフェニル）−シクロヘキサン−１，３−ジオールとパラセタモールを含む医薬の組み合わせ | |
| TR201004720T1 (tr) | Majör depresif bozukluğun tedavisi için o-desmetil venlafaksin | |
| JP2013530937A (ja) | 自己免疫疾患の処置剤 | |
| RU2015141118A (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза |